Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

FUNFIT

Financiado

Cerrado

Fungal resistance to antifungals is promoted by cell heterogeneity

The number of people who die from fungal infections is estimated to be equivalent to or greater than the numbers that die from either tuberculosis or malaria. There are only 3 classes of antifungal drugs available to treat these i... ver más

31/05/2017

UNIVERSITY OF MANC...

195K€

Presupuesto del proyecto: 195K€

Líder del proyecto

THE UNIVERSITY OF MANCHESTER No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2017-05-31

MSCA-IF-2014-EF: Marie Skłodowska-Curie Individual F...

I+D

Cerrada hace 10 años

0% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

UNIVERSITY OF MANCHESTER

195.45K€ | Lider

Proyectos interesantes

TARAF

Medical Technol...

Data Science

188K€ Cerrado

SAF2008-04143

Medical Technol...

54K€ Cerrado

PDC2022-133266-I00

Medical Technol...

Data Science

150K€ Cerrado

FungalTolerance

Medical Technol...

Data Science

10M€ Cerrado

SYBARIS

Medical Technol...

Data Science

6M€ Cerrado

ARIADNE

Medical Technol...

Biotechnology

3M€ Cerrado

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Duración del proyecto: 27 meses Fecha Inicio: 2015-02-24
Fecha Fin: 2017-05-31

Líder del proyecto

THE UNIVERSITY OF MANCHESTER No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 195K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto The number of people who die from fungal infections is estimated to be equivalent to or greater than the numbers that die from either tuberculosis or malaria. There are only 3 classes of antifungal drugs available to treat these invasive diseases and resistance against these drugs is increasing. In this study I will investigate how antifungal resistance is impacted by cell heterogeneity in the pathogenic fungus Aspergillus fumigatus. The main hypothesis that I will test is that fungal cell heterogeneity provides subpopulations of cells with greater fitness to resist antifungal treatment. I will determine: (1) which features of three distinct fungal cell types contribute to cell heterogeneity; (2) which cell types and subpopulations of these cells show highest resistance or survival against antifungals; and (3) the roles of septal plugging and cell ploidy in the mechanistic basis of fungal cell heterogeneity. Cutting edge technologies that will be used in this study will include: (1) flow cytometry and fluorescence activated cell sorting (FACS) to identify and select cell subpopulations to test their antifungal resistance, (2) automated, high throughput, high content live cell imaging to analyse the resistance of single cells to antifungals, (3) advanced live-cell imaging techniques including GFP photoactivation and fluorescence recovery after photobleaching (FRAP) to identify septal pore plugging; and (4) laser microdissection to further analyse septal pore plugging. With these advanced techniques I will study the mechanistic basis of fungal resistance mediated by cell heterogeneity. My results will ultimately show how fungal cell heterogeneity impacts fitness against antifungal drugs and they will be the starting point for designing novel antifungal therapies that reduce this fitness.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores